New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
11:12 EDTJAZZJazz Pharmaceuticals price target lowered to $151 from $182 at Cantor
Cantor believes an overhang remains on Jazz Pharmaceuticals as the company continues to dispute the wording in the final REMS for Xyrem and the firm now sees a lower chance that the company may be taken over in the next year. Cantor lowered its price target on Jazz to $151 from $182 and maintains its Hold rating on the shares.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2014
07:54 EDTJAZZJazz Pharmaceuticals management to meet with UBS
Subscribe for More Information
September 24, 2014
07:55 EDTJAZZJazz Pharmaceuticals management to meet with UBS
Meetings to be held in Geneva/Zurich on September 24 hosted by UBS.
September 16, 2014
11:51 EDTJAZZOECD looks to close tax loopholes with new proposals
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use